Penumbra Business Summary

Penumbra Inc. (PEN) is a global healthcare leader specializing in interventional therapies, generating revenue primarily through the direct sale of high-margin, single-use medical devices to hospitals and surgical centers. Its business model is centered on two primary segments: Thrombectomy, which leverages proprietary computer-assisted vacuum aspiration (CAVT) technologies like the Lightning and Thunderbolt systems to treat ischemic stroke and pulmonary embolism; and Embolization and Access, which focuses on neurovascular aneurysms and peripheral vascular solutions. As of March 2026, the company is operating under a definitive agreement to be acquired by Boston Scientific for approximately $14.5 billion, a strategic merger aimed at integrating Penumbra’s dominant clot-removal portfolio into a broader global cardiovascular platform. Penumbra competes directly with Medtronic, Stryker, Terumo, and Johnson & Johnson, maintaining a superior market position as a specialized, high-growth innovator in mechanical aspiration compared to the more diversified portfolios of its larger peers. The company was co-founded in 2004 by Adam Elsesser and Dr. Arani Bose, a partnership that combines corporate scaling expertise with deep clinical innovation. Adam Elsesser serves as Chairman and CEO, having previously led Smart Therapeutics through its acquisition by Boston Scientific, while Dr. Bose, the Chief Innovator, is a pioneer in neuro-interventional radiology who developed the company’s foundational technologies. The current leadership team includes President Shruthi Narayan and CFO Maggie Yuen, a seasoned executive with a background at Thermo Fisher and Abbott. Penumbra’s strategic direction is further guided by a robust Board of Directors featuring notable members such as Don Knauss, former CEO of Clorox, and Surbhi Sarna, founder of nVision Medical. This leadership blend of clinical pedigree and operational discipline has been instrumental in Penumbra’s evolution from a neurovascular startup into a multi-billion dollar cornerstone of the vascular intervention market.